Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Anxiety Disorders
Cortex Initiates Enrollment in Opiate Induced Respiratory Depression Clinical Trial in Germany Today
April 18th, 2008
Cortex Pharmaceuticals, Inc. (AMEX: COR, http://www.cortexpharm.com), was notified by the German regulatory agency which approves the use of narcotic drugs that it can proceed with the trial which will use alfentanil, an opiate analgesic. With this approval the enrollment of subjects into the dose response study evaluating the ability of CX717 to prevent respiratory depression caused by opiate analgesics has begun. The study is a placebo controlled, double blinded, cross-over design with three doses of CX717compared to placebo. Depending on the pace of subjects being enrolled, Cortex at this point believes that top-line data will be available from this study by the end of June,...
Source: Health Business Week (2008-04-18)
|
